Portfolio

Onyx Motion’s digital coach Swish featured on Canada AM

April 14, 2015
Susanne Staer
Media Coverage

Swish, by Onyx Motion, is a wearable virtual coach that helps basketball players improve their shooting technique while emulating their hardcourt heroes.

UTEST company Onyx Motion‘s lead product, Swish — a basketball virtual coach that currently works with Android Wear smartwatches to help basketball athletes to improve their shooting technique and emulate their heroes — was featured on Canada AM this morning.

Watch the clip of Onyx Motion’s Swish on Canada AM, CTV’s flagship morning show. Product feature plays after advertisements and begins at 1:40 mark.

Think you’ve got an equally great software-based idea for a start-up? UTEST is currently recruiting for its fourth cohort.

Tom Emrich, a Toronto-based consultant and blogger who specializes in mobile, tablets and wearable technology, presented Swish to Canada AM hosts Marci Ien, Beverly Thomson and Jeff Hutcheson using a Sony SmartWatch 3.

“The application takes your form, measures it and, using the motion sensor of the smartwatch, compares it to experienced players’ data and provides you with a tip,” Emrich explained. “It’s really trying to make sure your next shot is going to be a slam dunk.”

Onyx Motion is part of UTEST’s third cohort. The incubator program, which MaRS Innovation co-directs with the University of Toronto. UTEST is currently recruiting companies to its fourth cohort.

Globe and Mail features UTEST company eQOL’s home dialysis technology

April 13, 2015
Susanne Staer
eQOL Inc.

“When Binh Nguyen, then a graduate student in biomedical engineering at the University of Toronto, was working in the renal engineering department of a local hospital, he was struck by what he felt was a suboptimal setup for dialysis treatment,” writes Jordana Dixon in “Health startup helps patients become more independent,” for the Globe and Mail on April 13, 2015.

eQOL Inc. is a University of Toronto and MaRS Innovation start-up company that participated in and graduated from the University of Toronto Early-Stage Technology (UTEST) program’s second cohort.

UTEST is currently accepting applications for its fourth cohort.

Here’s an excerpt from the article:

Taking these complications into consideration, Mr. Nguyen envisioned an all-encompassing lateral system that would optimize the process of in-home dialysis utilizing technology, but most importantly, improving patient experience.

How to get accepted into the UTEST start-up incubator: Drive and differentiation

April 1, 2015
Susanne Staer
CoursePeer

UTEST is now accepting applications to Cohort 4

Editor’s note: As of today, the University of Toronto Early-Stage Technology (UTEST) program, which MaRS Innovation co-directs with the University of Toronto, is accepting applications for Cohort 4. The full application is available on the UTEST website.

In meantime, it’s our pleasure to reprint Brianna Goldberg’s “day-in-the-life-of-an-entrepreneur” feature on Cohort 3 company Nvest, published for U of T News.

Jackie Yan focuses on tweaking his PowerPoint slide deck despite the chaos unfolding around him.

Nvest team at work in front of a computer

Near the entrance to the office space he shares with teams from the six other startups that are part of the UTEST accelerator program, a phone spits distorted tones of an investment-related conference call at Hanna Tomory, CEO of a fatigue-management start-up called Syncadian, as she scratches a list of notes.

A few steps down the hall, Marissa Wu, founder of the digital sports coaching wearable startup called Onyx Motion, goes over presentation notes with her co-founder Vivek Kesarwani. They discuss the finer points of athlete training with the intensity of so many layup drills performed on the basketball net propped against the wall of their desk space.

Across the table in the conference room where Yan is feverishly editing his slides, James McCrae pieces together 3D sculptures of horses, wasps and dinosaurs created with software from his start-up, FlatFab.

“We’re hoping to make more stable structures with our 1.0 design, maybe integrating finger-joints,” McCrae explains as he prepares to demo FlatFab’s wares for a video crew from the Privy Council Office in Ottawa, Ontario.

The videographers are producing a video about MaRS Innovation today, which co-directs the UTEST accelerator program with the University of Toronto, and are capturing b-roll of UTEST founders at work on their ventures. With seven companies currently sharing the working space, there’s always something happening.

Smartphones and mobile tablets becoming mainstays for clinicians

VitalHub’s partnership with Microsoft and Intel for Seattle Children’s Hospital pilot and British Columbia contracts featured in Canadian Healthcare Technology

“As hospital invest continue to invest in mobile solutions, doctors and nurses are more likely to be texting on their smartphones or swiping their fingers across a tablet PCs than tapping away on desktop computers,” Dianne Daniel writes in the April 2015 issue of Canadian Healthcare Technology in an article titled, “Smartphones and mobile tablets are becoming essential tools for clinicians” (page 12-13 of the print edition).

VitalHub Corp, a Mount Sinai Hospital spun-off through partnership with MaRS Innovation, is among the healthcare technology companies delivering services to hospitals as part of this trend.

Daniel writes:

One company that is giving clinicians the option to use their preferred device — whether iOS, Android, or Windows 8, smartphone or tablet — is VitalHub Corp, a Mount Sinai spin-off launched in Toronto in 2009. “We have found that many hospitals provide their nurses with mobile devices and can therefore select the platform they would prefer for those users, but physicians are generally expected to be BOD,” said VitalHub CEO Lisa Crossley. “So for a mobile solution to be practical, it has to be cross-platform.”

UTEST company Nvest is bringing accountability to investment recommendations

March 30, 2015
Susanne Staer
Media Coverage

Nvest Logo Nvest, a University of Toronto company, is gaining traction as a financial technology (or fintech) start-up to watch. Nvest is part of the third UTEST cohort, which is an early-stage technology incubator program co-directed by MaRS Innovation and U of T (read more about the UTEST program in our portfolio section).

In the last month, Nvest has been profiled in both TechVibes and Investment Executive as a company to watch both as a social network for stock picking and as a tool to bringing accountability to investment recommendations.

Jacob Serebrin writes for TechVibes:

Fredrick Zhou says there’s something wrong with the way people recommend stocks online.

“People don’t take responsibility for their actions, their words and their recommendations,” Zhou says.

He’s the co-founder and CEO of Nvest, a new social network for stock pickers that he says will bring accountability and transparency to a broken system.

Sunnybrook forms new industry partnership to advance WaveCheck technology

Co-development agreement, brokered by MaRS Innovation, to advance ultrasound chemotherapy monitoring technology as clinical tool

TORONTO (March 12, 2015) — Sunnybrook Health Sciences Centre and MaRS Innovation today announced a co-development agreement for WaveCheck, an ultrasound technology that transforms conventional equipment so that physicians can monitor a breast cancer tumour’s response to chemotherapy.

This announcement was covered in Biotechnology Focus, Aunt Minnie.com (radiology blog), dotmed.com, Bio-Medicine.org, Bloomberg Business and Research Views.

The partnership with GE Healthcare, brokered by MaRS Innovation, seeks to develop WaveCheck as a clinical tool that gives clinicians rapid, improved transparency to determine if breast cancer tumors are responding to chemotherapy.

WaveCheck is a clinical technique invented, refined and tested by Dr. Gregory Czarnota, chief of Radiation Oncology at Sunnybrook’s Odette Cancer Centre, and Michael C. Kolios, professor of Physics and associate dean, Research and Graduate Studies, in Ryerson University’s Faculty of Science. Their technology uses ultrasound to visually demonstrate whether chemotherapy is destroying a breast cancer tumour at the beginning of chemotherapy treatment in as little as one week. If applied to the clinic, this knowledge has the power to transform patient experience, since existing breast cancer patients typically wait until the end of treatment, anywhere from four to six months, to know if their tumor has responded.

In early clinical testing, WaveCheck’s inexpensive, non-invasive, image-guided technology (shown here) shows promise as an accurate, efficient way to monitor tumour response. Sunnybrook has partnered with GE Healthcare to co-develop WaveCheck as a clinical tool.

In early clinical testing, WaveCheck’s inexpensive, non-invasive, image-guided technology shows promise as an accurate, efficient way to monitor tumour response, opening the door to tailored treatment.

The agreement leverages GE Healthcare’s extensive ultrasound technology and market expertise in bringing new ultrasound innovations to global hospitals and clinics with Sunnybrook’s leadership in oncology research and cancer care through the Odette Cancer Centre.

ChipCare closes oversubscribed $5 million series A financing

With lead investment from Puffin Partners, the Ontario, Canada-based company is taking lifesaving blood-testing technology to low- and middle-income countries

ChipCare device — ChipCare’s technology will provide simple-to-use, mobile, lab-quality blood testing for remote health settings. The **University of Toronto** start-up company’s first HIV-related test, targeted at linking people with HIV to appropriate treatments, is scheduled to hit the market in late 2016.

TORONTO, March 3, 2015 — ChipCare Corporation, a University of Toronto start-up company commercializing a handheld, blood-testing platform for HIV and other infectious and non-communicable diseases has closed a $5.045 million Series A financing to bring its first-generation product to market while further developing the platform’s next generation products.

The Wall Street Journal‘s Venture Capital Dispatch blog, Yonge Street Media, BetaKit and PEHub covered this announcement, along with the University of Toronto’s news site and a follow-up BetaKit article on how smartphones and start-ups are increasing access to healthcare. Information about past ChipCare investment rounds and other company information is available in our ChipCare news archive.

Insufficient access in remote health settings to simple, accurate and affordable diagnostic tests makes it difficult to provide timely, evidence-based clinical care. Current technology within central laboratories cannot fulfill the existing need in remote health settings, including community level health facilities, remote communities, emergency departments, ICUs and doctors’ offices. The result is millions of preventable deaths from infectious and non-communicable diseases globally, reduced economic growth, and limited human development.

ChipCare’s technology will provide simple-to-use, mobile, lab-quality blood testing in remote health settings. The company’s first HIV-related test, targeted at linking people with HIV to appropriate treatments, is scheduled to hit the market in late 2016. The company is developing other products that leverage unique attributes of ChipCare’s technology.

Puffin Partners, LP, of Dallas, Texas led the financing round, which includes existing investors MaRS Innovation and Maple Leaf Angels, and new investors, including the Winfield Venture Group, Epic Capital, and additional Canadian and U.S. Angel investors.

Triphase Accelerator announces new cancer collaboration with Sunnybrook Research Institute

February 27, 2015
Susanne Staer
Industry Partners

TORONTO and SAN DIEGO (Feb. 26, 2015) — Triphase Accelerator Corporation has entered into an academic center collaboration with Sunnybrook Research Institute (SRI), the research arm of Sunnybrook Health Sciences Centre, a MaRS Innovation member institution. MaRS Innovation is also a Triphase investor.

Under the agreement, SRI will assist in the development of Triphase’s novel, first-in-class, fully human bi-specific antibody TRPH 011 and evaluate the role of bifunctional targeting of VEGFR-2 and TIE 2 receptors in cancer. TRPH 011 binds and neutralizes VEGFR-2/KDR and TIE 2 receptors simultaneously, resulting in sustained inhibition of tumor growth and angiogenesis (the formation of new blood vessels from pre-existing vessels and a fundamental step in the transition of tumors from a benign to a malignant state).

Under the terms of the agreement, Triphase will provide funding to the laboratory of Dr. Robert S. Kerbel, senior scientist in the Biological Sciences Platform at SRI. Dr. Kerbel and his colleagues will evaluate TRPH 011 in preclinical pharmacology models. Triphase will use the findings to advance the TRPH 011 program toward an Investigational New Drug (IND) filing.

Portfolio round-up: UTEST, Nvest and Whirlscape news

February 26, 2015
Susanne Staer
Media Coverage

Sometimes there’s so much happening with the MaRS Innovation portfolio that it’s hard to stay on top of all the news. Here are a few UTEST program stories that we missed in February.

UTEST was named to FundThrough.com’s list of “6 Exciting Canadian Startup Accelerators to Watch in 2015.” Program co-directors Mike Betts and Kurtis Scissons point out that UTEST does take an equity position in the incubated companies and does not run on a grant basis as mentioned in the article. (It’s a sweetheart deal, but not that sweet.)

UTEST company Nvest was featured in a Globe and Mail story, “Next big sector to face disruption? Financial services” by Brenda Bouw. Here’s a quote:
“Another emerging fintech startup is Nvest, an early-stage, crowd-sourced stock recommendation platform. Nvest compiles recommendations from its users, many of which are average retail investors, and builds a performance history others can track. The credibility of recommendations is based on a user’s past performance. Nvest co-founder Fredrick Zhou likens it to LinkedIn for stock recommendations. ‘Nvest is a place where investors post their trading resume.’ Investors are taking notice. Nvest recently received funding from the University of Toronto Early Stage Technology program and it is in the process of pitching the business to angel investors.”

Ontario government announces over $400,000 for eQOL’s home dialysis technology

February 19, 2015
Susanne Staer
eQOL Inc.

SAULT STE. MARIE, February 13, 2015 — eQOL, a Sault Ste. Marie-based company working to enhance patient independence and a graduate of the second University of Toronto Early-Stage Technology (UTEST) incubator’s second cohort, has received $435,475 from the Ontario Government. David Orazietti, MPP for Sault Ste. Marie, made the announcement on February 13, 2015.

This announcement was covered by BetaKit, The Sault Star and SooToday.com.

The funding, which includes $415,000 through the Northern Ontario Heritage Fund Corporation (NOHFC) and $20,475 to hire an intern under the Northern Ontario Internship Program also through NOHFC, will allow eQOL to complete clinical studies using their Dialysis Platform for Communication, Assistance and Training (DiCAT) product.

David Orazetti and Binh Nguyan — MPP David Orazetti (left) and Binh Nguyan (centre), CEO of eQOL, at the Northern Ontario Internship Program announcement on February 13, 2014. Photo courtesy of SooToday.com.

“With this support from our government, eQOL is able to use their innovative new technology in clinical studies – the first step towards commercializing the technology,” said Orazietti. “This software will not only enhance the quality of life for dialysis patients, but will also benefit our health care system and community as it streamlines processes and alleviates strain on hospital resources.”

DiCAT, a mobile technology solution for independent/home dialysis, aims to simplify and reduce the intimidation that patients experience with this self-care process. Its iPad and web-based applications provide enhanced connectivity, access to resources, and process management, which will promote a shift from in-centre care to in-home care. Successfully completing the clinical study and implementing DiCAT will allow patients who live far away from healthcare centres to receive care at home without having to relocate, which will have a great impact in northern regions.